Please Wait
Applying Filters...
Menu
Xls
2D Structure
Also known as: 26171-23-3, 1-methyl-5-p-toluoylpyrrole-2-acetic acid, Tolectin, Tolmetine, Tolmetinum, Tolmetina [dcit]
Molecular Formula
C15H15NO3
Molecular Weight
257.28  g/mol
InChI Key
UPSPUYADGBWSHF-UHFFFAOYSA-N
FDA UNII
D8K2JPN18B

A non-steroidal anti-inflammatory agent (ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL) similar in mode of action to INDOMETHACIN.
Tolmetin is a Nonsteroidal Anti-inflammatory Drug. The mechanism of action of tolmetin is as a Cyclooxygenase Inhibitor.
1 2D Structure

2D Structure

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
2-[1-methyl-5-(4-methylbenzoyl)pyrrol-2-yl]acetic acid
2.1.2 InChI
InChI=1S/C15H15NO3/c1-10-3-5-11(6-4-10)15(19)13-8-7-12(16(13)2)9-14(17)18/h3-8H,9H2,1-2H3,(H,17,18)
2.1.3 InChI Key
UPSPUYADGBWSHF-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CC1=CC=C(C=C1)C(=O)C2=CC=C(N2C)CC(=O)O
2.2 Other Identifiers
2.2.1 UNII
D8K2JPN18B
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Anhydrous Tolmetin Sodium

2. Anhydrous, Tolmetin Sodium

3. Dihydrate Tolmetin Sodium

4. Mcn 2559

5. Mcn-2559

6. Mcn2559

7. Sodium Anhydrous, Tolmetin

8. Sodium, Tolmetin

9. Tolectin

10. Tolmetin Sodium

11. Tolmetin Sodium Anhydrous

12. Tolmetin Sodium, Anhydrous

13. Tolmetin Sodium, Dihydrate

2.3.2 Depositor-Supplied Synonyms

1. 26171-23-3

2. 1-methyl-5-p-toluoylpyrrole-2-acetic Acid

3. Tolectin

4. Tolmetine

5. Tolmetinum

6. Tolmetina [dcit]

7. Mcn-2559

8. Tolmetina

9. Tolmetino

10. Tolmetine [inn-french]

11. Tolmetinum [inn-latin]

12. Tolmetino [inn-spanish]

13. 1h-pyrrole-2-acetic Acid, 1-methyl-5-(4-methylbenzoyl)-

14. Mcn 2559

15. 2-(1-methyl-5-(4-methylbenzoyl)-1h-pyrrol-2-yl)acetic Acid

16. 2-[1-methyl-5-(4-methylbenzoyl)pyrrol-2-yl]acetic Acid

17. 1-methyl-5-(4-methylbenzoyl)-pyrrole-2-acetic Acid

18. 5-(p-toluoyl)-1-methylpyrrole-2-acetic Acid

19. Acido 1-metil-5-(p-tolnil)-pirrol-2-acetico

20. 2-[1-methyl-5-(4-methylbenzoyl)-1h-pyrrol-2-yl]acetic Acid

21. Pyrrole-2-acetic Acid, 1-methyl-5-p-toluoyl-

22. Chembl1020

23. D8k2jpn18b

24. [1-methyl-5-(4-methylbenzoyl)-1h-pyrrol-2-yl]acetic Acid

25. Chebi:71941

26. 1-methyl-5-p-toluoyl-pyrrole-2-acetic Acid

27. 2-{1-methyl-5-[(4-methylphenyl)carbonyl]-1h-pyrrol-2-yl}acetic Acid

28. Hsdb 3403

29. Tolmetin (usan/inn)

30. Mcn-2559-21-98

31. Einecs 247-497-2

32. Unii-d8k2jpn18b

33. Brn 0485305

34. Tolmetin [usan:inn:ban]

35. 1-methyl-5-(4-methylbenzoyl)-1h-pyrrole-2-acetic Acid

36. Acido 1-metil-5-(p-tolnil)-pirrol-2-acetico [spanish]

37. Spectrum_000935

38. Tolmetin [hsdb]

39. Tolmetin [usan]

40. Tolmetin [inn]

41. Tolmetin [jan]

42. Tolmetin [mi]

43. Tolmetin [vandf]

44. Prestwick0_000856

45. Prestwick1_000856

46. Prestwick2_000856

47. Prestwick3_000856

48. Spectrum2_001205

49. Spectrum3_000603

50. Spectrum4_000359

51. Spectrum5_001194

52. Tolmetin [who-dd]

53. Schembl3150

54. Oprea1_869397

55. Bspbio_000871

56. Bspbio_002106

57. Kbiogr_000797

58. Kbioss_001415

59. 5-22-06-00392 (beilstein Handbook Reference)

60. Bidd:gt0468

61. Divk1c_000213

62. Spbio_000990

63. Spbio_002792

64. Bpbio1_000959

65. Gtpl7311

66. Zinc2191

67. Dtxsid2043951

68. Kbio1_000213

69. Kbio2_001415

70. Kbio2_003983

71. Kbio2_006551

72. Kbio3_001606

73. Ninds_000213

74. Hms2090d06

75. Hms3886i03

76. Bcp09085

77. Hy-b1799

78. Bdbm50295287

79. Mfcd00599595

80. S4832

81. Akos015850645

82. Ccg-267033

83. Cs-w008734

84. Db00500

85. Gs-6529

86. Sb63879

87. Idi1_000213

88. Tolmetin 100 Microg/ml In Acetonitrile

89. Ncgc00094796-03

90. 1-methyl-5-p-toluoylpyrrole-2-aceticacid

91. Sbi-0051537.p002

92. Ft-0649942

93. Ft-0675272

94. 1-methyl- 5-(p-toluoyl)pyrrole-2-acetic Acid

95. C07149

96. D02355

97. 171t233

98. A818238

99. 1-methyl-5-(4-methylbenzoyl)pyrrole-2-acetic Acid

100. J-504975

101. Q3992411

102. Brd-k82562631-236-02-0

103. Brd-k82562631-325-03-9

104. F6782-4251

105. [1-methyl-5-(4-methyl-benzoyl)-1h-pyrrol-2-yl]-acetic Acid

106. [1-methyl-5-(4-methylbenzoyl)-1h-pyrrol-2-yl]acetic Acid #

107. [1-methyl-5-(4-methyl-benzoyl)-1h-pyrrol-2-yl]-acetic Acid(tolmetin)

108. Tlt

2.4 Create Date
2005-03-25
3 Chemical and Physical Properties
Molecular Weight 257.28 g/mol
Molecular Formula C15H15NO3
XLogP32.8
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count3
Rotatable Bond Count4
Exact Mass257.10519334 g/mol
Monoisotopic Mass257.10519334 g/mol
Topological Polar Surface Area59.3 Ų
Heavy Atom Count19
Formal Charge0
Complexity347
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Therapeutic Uses

Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors

National Library of Medicine's Medical Subject Headings online file (MeSH, 1999)


IN SEVERAL CONTROLLED STUDIES IN PT WITH RHEUMATOID ARTHRITIS, TOLMETIN REDUCED SEVERITY OF SYMPTOMS (...JOINT SWELLING, PAIN, NUMBER OF INFLAMED JOINTS, DURATION OF MORNING STIFFNESS). ITS EFFECTIVENESS WAS MAINTAINED WITH LONG-TERM USE (TWO YEARS). /TOLMETIN SODIUM/

American Medical Association, AMA Department of Drugs, AMA Drug Evaluations. 3rd ed. Littleton, Massachusetts: PSG Publishing Co., Inc., 1977., p. 388


EFFICACY...IN A DAILY DOSE OF ABOUT 1.2 G WAS COMPARABLE TO...3.9 G OF ASPIRIN DAILY. /OTHER/...STUDIES IN PT WITH RHEUMATOID ARTHRITIS INDICATED...DAILY DOSE OF ABOUT 1.2 G OF TOLMETIN WAS EQUALLY EFFECTIVE TO ABOUT 150 MG INDOMETHACIN. ...SIMILAR EFFECTIVENESS /COMPARED TO/ IBUPROFEN & PHENYLBUTAZONE. /TOLMETIN SODIUM/

American Medical Association, AMA Department of Drugs, AMA Drug Evaluations. 3rd ed. Littleton, Massachusetts: PSG Publishing Co., Inc., 1977., p. 388


...SHOWN TO BE EFFECTIVE IN TREATMENT OF JUVENILE RHEUMATOID ARTHRITIS; HOWEVER, THE NUMBER OF PT STUDIED WAS SMALL & ADDNL STUDIES ARE NECESSARY TO ESTABLISH THE EFFECTIVE DOSE. /TOLMETIN SODIUM/

American Medical Association, AMA Department of Drugs, AMA Drug Evaluations. 3rd ed. Littleton, Massachusetts: PSG Publishing Co., Inc., 1977., p. 389


For more Therapeutic Uses (Complete) data for TOLMETIN (14 total), please visit the HSDB record page.


4.2 Drug Warning

IN CLINICAL STUDIES, PEPTIC ULCER OCCURRED IN APPROX 2% OF PT. IT IS... ADVISABLE TO USE TOLMETIN CAUTIOUSLY IN PT WITH A HISTORY OF PEPTIC ULCER. /TOLMETIN SODIUM/

American Medical Association, AMA Department of Drugs, AMA Drug Evaluations. 3rd ed. Littleton, Massachusetts: PSG Publishing Co., Inc., 1977., p. 389


TOLMETIN DECR PLATELET ADHESIVENESS & INCR BLEEDING TIME; THUS, IT SHOULD NOT BE USED IN PT WITH BLEEDING DISORDERS. /TOLMETIN SODIUM/

American Medical Association, AMA Department of Drugs, AMA Drug Evaluations. 3rd ed. Littleton, Massachusetts: PSG Publishing Co., Inc., 1977., p. 389


TOLMETIN...COMMONLY PRODUCES GASTROINTESTINAL REACTIONS (25% OF RECIPIENTS), & THEY RANGE FROM TRANSIENT MILD EFFECTS, SUCH AS NAUSEA, TO SERIOUS REACTIONS REQUIRING CESSATION OF THERAPY. ... URTICARIA, HEADACHE, WATER RETENTION, DIZZINESS, & HYPERTENSION HAVE ALSO BEEN REPORTED. /TOLMETIN SODIUM/

Miller, R. R., and D. J. Greenblatt. Handbook of Drug Therapy. New York: Elsevier North Holland, 1979., p. 494


TOLMETIN CAUSES PSEUDOPROTEINURIA IN TESTS INVOLVING ACID PPT; THUS, OTHER METHODS FOR DETECTING PROTEINURIA SHOULD BE USED FOR PT RECEIVING THIS DRUG. /TOLMETIN SODIUM/

American Medical Association, AMA Department of Drugs, AMA Drug Evaluations. 3rd ed. Littleton, Massachusetts: PSG Publishing Co., Inc., 1977., p. 389


For more Drug Warnings (Complete) data for TOLMETIN (8 total), please visit the HSDB record page.


4.3 Drug Indication

For the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis, including the treatment of acute flares long-term management. Also for treatment of juvenile rheumatoid arthritis.


FDA Label


5 Pharmacology and Biochemistry
5.1 Pharmacology

Tolmetin is a nonsteroidal anti-inflammatory agent. Studies in animals have shown tolmetin to possess anti-inflammatory, analgesic and antipyretic activity. In the rat, tolmetin prevents the development of experimentally induced polyarthritis and also decreases established inflammation. In patients with either rheumatoid arthritis or osteaoarthritis, tolmetin is as effective as aspirin and indomethacin in controlling disease activity, but the frequency of the milder gastrointestinal adverse effects and tinnitus was less than in aspirin-treated patients, and the incidence of central nervous system adverse effects was less than in indomethacin-treated patients. In patients with juvenile rheumatoid arthritis, tolmetin is as effective as aspirin in controlling disease activity, with a similar incidence of adverse reactions. tolmetin has produced additional therapeutic benefit when added to a regimen of gold salts and, to a lesser extent, with corticosteroids. Tolmetin should not be used in conjunction with salicylates since greater benefit from the combination is not likely, but the potential for adverse reactions is increased.


5.2 MeSH Pharmacological Classification

Anti-Inflammatory Agents, Non-Steroidal

Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)


Cyclooxygenase Inhibitors

Compounds or agents that combine with cyclooxygenase (PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES) and thereby prevent its substrate-enzyme combination with arachidonic acid and the formation of eicosanoids, prostaglandins, and thromboxanes. (See all compounds classified as Cyclooxygenase Inhibitors.)


5.3 FDA Pharmacological Classification
5.3.1 Active Moiety
TOLMETIN
5.3.2 FDA UNII
D8K2JPN18B
5.3.3 Pharmacological Classes
Established Pharmacologic Class [EPC] - Nonsteroidal Anti-inflammatory Drug
5.4 ATC Code

M - Musculo-skeletal system

M01 - Antiinflammatory and antirheumatic products

M01A - Antiinflammatory and antirheumatic products, non-steroids

M01AB - Acetic acid derivatives and related substances

M01AB03 - Tolmetin


M - Musculo-skeletal system

M02 - Topical products for joint and muscular pain

M02A - Topical products for joint and muscular pain

M02AA - Antiinflammatory preparations, non-steroids for topical use

M02AA21 - Tolmetin


5.5 Absorption, Distribution and Excretion

Absorption

Rapidly and almost completely absorbed with peak plasma levels being reached within 30-60 minutes after an oral therapeutic dose.


THE DRUG IS RAPIDLY ABSORBED AFTER ORAL ADMIN, PEAK PLASMA LEVELS OCCUR IN 30 TO 60 MIN. IT IS EXCRETED LARGELY IN URINE, PRIMARILY AS CONJUGATES OR METABOLITES. ITS PLASMA HALF-LIFE IS APPROX 1 HR. /TOLMETIN SODIUM/

American Medical Association, AMA Department of Drugs, AMA Drug Evaluations. 3rd ed. Littleton, Massachusetts: PSG Publishing Co., Inc., 1977., p. 389


GI ABSORPTION IS ABOUT 90% OR GREATER...WITH PEAK LEVELS WITHIN 20-60 MIN FOR TOLMETIN... PROTEIN BINDING IS EXTENSIVE, BEING 90% OR GREATER... HEPATIC BIOTRANSFORMATION & RENAL EXCRETION WITH SOME FECAL EXCRETION OF METABOLITES ARE THE MEANS OF ELIMINATION. /TOLMETIN SODIUM/

Miller, R. R., and D. J. Greenblatt. Handbook of Drug Therapy. New York: Elsevier North Holland, 1979., p. 493


TOLMETIN IS RAPIDLY & COMPLETELY ABSORBED FOLLOWING ORAL ADMIN TO MAN, & CONCN ACHIEVED IN PLASMA ARE NOT REDUCED BY CONCOMITANT ADMIN OF GASTRIC ANTACIDS. PEAK CONCN ARE ACHIEVED 20-60 MIN AFTER ORAL ADMIN, & T/2 IN PLASMA IS BETWEEN 1 & 3 HR.

Gilman, A. G., L. S. Goodman, and A. Gilman. (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 6th ed. New York: Macmillan Publishing Co., Inc. 1980., p. 709


AFTER ABSORPTION, TOLMETIN IS EXTENSIVELY (99%) BOUND TO PLASMA PROTEINS. VIRTUALLY ALL OF THE DRUG CAN BE RECOVERED IN URINE AFTER 24 HR; SOME IS UNCHANGED (17%), BUT MOST IS CONJUGATED (10%) OR OTHERWISE METABOLIZED. THE MAJOR METABOLITE TRANSFORMATION IS DECARBOXYLATION.

Gilman, A. G., L. S. Goodman, and A. Gilman. (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 6th ed. New York: Macmillan Publishing Co., Inc. 1980., p. 709


TOLMETIN SODIUM WAS RAPIDLY & COMPLETELY ABSORBED (PEAK TIME, 20-60 MIN) & ELIMINATED RAPIDLY FROM PLASMA WITH BIPHASIC DECAY CURVE & ELIMINATION T/2 OF APPROX 2.1 HR.

GRINDEL JM ET AL; CLIN PHARMACOL THER 26(1) 122 (1979)


5.6 Metabolism/Metabolites

Essentially all of the administered dose is recovered in the urine in 24 hours either as an inactive oxidative metabolite or as conjugates of tolmetin.


URINE METABOLITES 1-METHYL-5-(4-CARBOXYBENZOYL)-1H-PYRROLE-2-ACETIC ACID & TOLMETIN GLUCURONIDE NOTED AFTER TOLMETIN SODIUM.

GRINDEL JM ET AL; CLIN PHARMACOL THER 26(1) 122 (1979)


Tolmetin has known human metabolites that include Tolmetin glucuronide.

S73 | METXBIODB | Metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560


5.7 Biological Half-Life

Biphasic elimination from the plasma consisting of a rapid phase with a half-life of one to 2 hours followed by a slower phase with a half-life of about 5 hours.


5.8 Mechanism of Action

The mode of action of tolmetin is not known. However, studies in laboratory animals and man have demonstrated that the anti-inflammatory action of tolmetin is not due to pituitary-adrenal stimulation. Tolmetin inhibits prostaglandin synthetase in vitro and lowers the plasma level of prostaglandin E in man. This reduction in prostaglandin synthesis may be responsible for the anti-inflammatory action. Tolmetin does not appear to alter the course of the underlying disease in man.


ALTHOUGH IT DIFFERS CHEMICALLY FROM ASPIRIN & OTHER NONSTEROIDAL ANTI-INFLAMMATORY AGENTS, ITS PHARMACOLOGIC PROPERTIES ARE SIMILAR. /TOLMETIN SODIUM/

American Medical Association, AMA Department of Drugs, AMA Drug Evaluations. 3rd ed. Littleton, Massachusetts: PSG Publishing Co., Inc., 1977., p. 388


...INHIBITS PROSTAGLANDIN SYNTHETASE IN VITRO. IT ALSO HAS BEEN SHOWN TO LOWER PLASMA LEVEL OF PROSTAGLANDIN E IN MAN. HOWEVER, SIGNIFICANCE OF THESE ACTIONS IN RELATION TO CLINICAL EFFECTS IS NOT KNOWN. /TOLMETIN SODIUM/

American Medical Association, AMA Department of Drugs, AMA Drug Evaluations. 3rd ed. Littleton, Massachusetts: PSG Publishing Co., Inc., 1977., p. 389